Addition of sodium glucose cotransporter 2 (SGLT2) inhibitor to glucagon-like peptide-1 (GLP-1) receptor agonist therapy in obese people with Type 2 diabetes and suboptimal glycaemic control

被引：0
|
作者：
Curtis, L. R. [1 ]
Walker, J. I. [1 ]
Knott, J. [1 ]
Partridge, H. L. [1 ]
机构：
[1] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Diabet & Endocrine Ctr, Bournemouth, Dorset, England
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P529
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [31] SGLT2 inhibitor and GLP-1 analogue combination therapy in Type 2 diabetes
    Bashir, J.
    Stephens, J.
    Anderson, R.
    Hayes, J.
    Elamin, O.
    Lloyd, A.
    DIABETIC MEDICINE, 2016, 33 : 165 - 166
  • [32] THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1(GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) INHIBITORS ON TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT
    Hiramatsu, Takeyuki
    Okumura, Shota
    Iguchi, Daiki
    Furuta, Shinji
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1350 - 1350
  • [33] FACTORS ASSOCIATED WITH SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2I) AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) PRESCRIPTIONS AMONG WOMEN VETERANS
    Ali, Sehrish
    Ramsey, David
    Crowley, Susan
    Navaneethan, Sankar
    Gregg, Lucile Parker
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S68 - S68
  • [34] Medication Adherence to SGLT2 Inhibitors vs. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Meta-Analysis
    Sussman, Whitney
    Weeda, Erin R.
    Johnson, Conner Elizabeth
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [35] Preserved Inhibitory Effect of Glucagon-Like Peptide-1 (GLP-1) on Glucagon Secretion in Type 2 Diabetes Mellitus
    Hare, Kristine J.
    Knop, Filip K.
    Asmar, Meena
    Larsen, Steen
    Madsbad, Sten
    Holst, Jens J.
    Vilsboll, Tina
    DIABETES, 2009, 58 : A372 - A372
  • [36] Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
    Palmer, Suetonia C.
    Tendal, Britta
    Mustafa, Reem A.
    Vandvik, Per Olav
    Li, Sheyu
    Hao, Qiukui
    Tunnicliffe, David
    Ruospo, Marinella
    Natale, Patrizia
    Saglimbene, Valeria
    Nicolucci, Antonio
    Johnson, David W.
    Tonelli, Marcello
    Rossi, Maria Chiara
    Badve, Sunil, V
    Cho, Yeoungjee
    Nadeau-Fredette, Annie-Claire
    Burke, Michael
    Faruque, Labib, I
    Lloyd, Anita
    Ahmad, Nasreen
    Liu, Yuanchen
    Tiv, Sophanny
    Millard, Tanya
    Gagliardi, Lucia
    Kolanu, Nithin
    Barmanray, Rahul D.
    McMorrow, Rita
    Cortez, Ana Karina Raygoza
    White, Heath
    Chen, Xiangyang
    Zhou, Xu
    Liu, Jiali
    Rodriguez, Andrea Flores
    Gonzalez-Colmenero, Alejandro Diaz
    Wang, Yang
    Li, Ling
    Sutanto, Surya
    Solis, Ricardo Cesar
    Gonzalez-Colmenero, Fernando Diaz
    Rodriguez-Gutierrez, Rene
    Walsh, Michael
    Guyatt, Gordon
    Strippoli, Giovanni F. M.
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 372
  • [37] Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium!glucose cotransporter 2 inhibitor? Or maybe both?
    Patoulias, Dimitrios
    Papadopoulos, Christodoulos
    Karagiannis, Asterios
    Doumas, Michael
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2022, 98 : 125 - 127
  • [38] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Hiep Nguyen
    Robert Dufour
    Amanda Caldwell-Tarr
    Advances in Therapy, 2017, 34 : 658 - 673
  • [39] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Nguyen, Hiep
    Dufour, Robert
    Caldwell-Tarr, Amanda
    ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
  • [40] ASSOCIATION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS WITH THE RISK OF DEVELOPING DEMENTIA IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
    Wang, J.
    Toulis, K.
    Gokhale, K.
    Adderley, N. J.
    Clark, D.
    Dhalla, S.
    Seck, D.
    Nirantharakumar, K.
    Eteve-Pitsaer, C.
    VALUE IN HEALTH, 2023, 26 (12) : S41 - S42
12345